Key result
Percutaneous left atrial appendage closure was successful in 100% of 17 patients with thrombus irresponsive to antithrombotic therapy, with no procedural complications or clinical thromboembolism.
Why the study?
Does percutaneous left atrial appendage closure safely prevent thromboembolism in patients with left atrial appendage thrombus irresponsive to antithrombotic therapy?
Observational (n=17)
Yes
Does percutaneous left atrial appendage closure safely prevent thromboembolism in patients with left atrial appendage thrombus irresponsive to antithrombotic therapy?
Percutaneous left atrial appendage closure appears to be a feasible and safe treatment option for patients with LAA thrombus irresponsive to antithrombotic therapy, including those with mechanical valve prostheses.
May support LAA closure in refractory thrombus; leaves open confirmation in randomized trials.
We analyzed clinical experience with percutaneous closure of instances of left atrial appendage with thrombus (LAAT) irresponsive to antithrombotic therapy in patients treated in three high-volume cardiology centers. Clinical and procedural data regarding consecutive patients who underwent percutaneous left atrial appendage closure (PLAAC) due to LAAT were retrospectively analyzed. The study population consisted of 17 patients (11 men; 68 ± 14 years; CHA2DS2VASC 4.7 ± 1.9; HASBLED 3 (0–5)) with LAAT confirmed by transesophageal echocardiography, and included 5 patients with mechanical heart valves. Most of the patients (94.1%) received anticoagulation therapy before PLAAC. All LAATs were located in distal portions of the appendage and occupied less than 30% of its volume. Occluding-device implantation was successful in 17 patients; in one, a residual leak was disclosed. Appropriate positioning of occluders required more than 1 attempt in 6 individuals (35.3%); in 3 others (17.6%), the subjects’ devices had contact with thrombi. No procedural complications were noted. Midterm follow-up (median: 10 months) revealed no procedure-related complications or clinically diagnosed thromboembolism. Transesophageal echocardiography (TEE) performed after six months revealed device-related thrombus in one patient. We concluded that LAAT irresponsive to antithrombotic therapy might be effectively treated with PLAAC, even in patients with mechanical-valve prostheses.
No takes yet. Share an insight, caveat, or question.
Kaczmarek et al. (2021) conducted an observational in Left atrial appendage with thrombus (LAAT) irresponsive to antithrombotic therapy (n=17). Percutaneous left atrial appendage closure (PLAAC) was evaluated on Successful occluding-device implantation. Percutaneous left atrial appendage closure was successful in 100% of 17 patients with thrombus irresponsive to antithrombotic therapy, with no procedural complications or clinical thromboembolism.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: